Corporate GovernanceJun 23, 2026, 05:22 PM
FibroBiologics Stockholders Approve 2026 Equity & Incentive Plan
AI Summary
FibroBiologics, Inc. stockholders approved the 2026 Equity and Incentive Compensation Plan, which succeeds the 2022 Stock Plan. The new plan makes 2,061,968 shares available for awards, with an "evergreen" provision to increase shares annually. Additionally, stockholders elected Pete O’Heeron as a Class III director to serve until the 2029 Annual Meeting and ratified WithumSmith+Brown, PC as the independent registered public accounting firm for 2026.
Key Highlights
- Stockholders approved the 2026 Equity and Incentive Compensation Plan.
- The 2026 Plan makes 2,061,968 shares available for awards, including 2,000,000 new shares.
- An "evergreen" provision will add shares annually from 2027-2036, up to 4% of outstanding common stock.
- Non-employee directors' compensation is capped at $800,000 per calendar year.
- Pete O’Heeron was elected as a Class III director until the 2029 Annual Meeting.
- WithumSmith+Brown, PC was ratified as the independent auditor for 2026.
- Stacy Coen did not stand for re-election, and her term as a Class III director expired.
Price Impact
More from FBLG